
|Articles|October 1, 2003
Clinical Trials Successful
Auckland, New Zealand - Intradermal injection of a purified cell wall component from heat-killed Mycobacterium vaccae may one day be used to treat children with severe atopic dermatitis, if a clinical program carried out by a New Zealand company continues to be successful.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Sister Clinicians Highlight Cross-Specialty Collaboration in Dermatology and Podiatry
2
Expert Tips for Treating Vitiligo Shared at Elevate-Derm Conference
3
A Dual mRNA Vaccine Against Merkel Cell Carcinoma Shows Synergy with PD-1 Blockade
4
Tips for Improving Rosacea Recognition in Patients With Skin of Color at Elevate-Derm
5



















